Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.63 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.50 |
| ▸ | INSR | P06213 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758553 | 0.94 | EGFR (0.66) | EGFRBTKMETALKINSR | |
| SCHEMBL23304000 | 0.94 | EGFR (0.66) | EGFRBTKMETALKINSR | |
| SCHEMBL24581821 | 0.91 | EGFR (0.73) | EGFRBTKMETALKINSR | |
| SCHEMBL23302543 | 0.89 | EGFR (0.79) | EGFRBTKALK | |
| SCHEMBL23302527 | 0.89 | EGFR (0.80) | EGFRBTKMETALKINSR | |
| SCHEMBL24581823 | 0.89 | EGFR (0.68) | EGFRBTKMETALKINSR | |
| SCHEMBL23302538 | 0.84 | EGFR (0.72) | EGFRBTKMETALKINSR | |
| SCHEMBL23302583 | 0.83 | EGFR (0.82) | EGFRBTKMETALK | |
| SCHEMBL29758554 | 0.83 | EGFR (0.82) | EGFRBTKMETALK | |
| SCHEMBL23303085 | 0.82 | EGFR (0.67) | EGFRBTKMETALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021085888-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 온코빅스 | 2021-05-06 | — | — | WO | claimed |
| US-20220204492-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2022-06-30 | — | — | US | disclosed |
| WO-2021085888-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 온코빅스 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204492-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EGFR, ALK, FGFR1 | EGFR 1/4885BTK 226/4885MET 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.